Knuechel R, Wieland W, Nicolai H, Hofstaedter F
Institut für Pathologie der Universität Regensburg.
Verh Dtsch Ges Pathol. 1993;77:204-8.
In order to find additional ways to classify bladder cancer, multiparameter analysis with antibodies against urothelial associated-glycoproteins (UAGAb: Uro1, -5, -9, -10; Signet) and cytokeratins (CKAb: KL1, Immunotech) were used in parallel with DNA staining. Single cell suspensions of 21 bladder cancer specimens (4pTaG1, 9pTaG2, 1pT1G2, 2 > pT2G2, 5 > pT2G3) were stained. Preliminary data showed that the proportion of UAGAb positive cells have to be related to the pan-urothelial marker Uro5, since percentage of urothelial cells was variable (30-97%). Phenotypic differences found in different stages of tumor will be described. Selection of tumor cells by UAG did result in higher precision to determine tumor S-phase fraction, and helped select tetraploid tumors. The methodology is best applicable to pTa and pT1-tumors and prospective analysis of these tumors has started.
为了找到膀胱癌的其他分类方法,将抗尿路上皮相关糖蛋白(UAGAb:Uro1、-5、-9、-10;Signet)和细胞角蛋白(CKAb:KL1,Immunotech)的多参数分析与DNA染色并行使用。对21例膀胱癌标本(4例pTaG1、9例pTaG2、1例pT1G2、2例>pT2G2、5例>pT2G3)的单细胞悬液进行染色。初步数据表明,UAGAb阳性细胞的比例必须与泛尿路上皮标志物Uro5相关,因为尿路上皮细胞的百分比是可变的(30%-97%)。将描述在肿瘤不同阶段发现的表型差异。通过UAG选择肿瘤细胞确实提高了确定肿瘤S期分数的精度,并有助于选择四倍体肿瘤。该方法最适用于pTa和pT1期肿瘤,并且已经开始对这些肿瘤进行前瞻性分析。